These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 10048974)
1. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Tseng YL; Hong RL; Tao MH; Chang FH Int J Cancer; 1999 Mar; 80(5):723-30. PubMed ID: 10048974 [TBL] [Abstract][Full Text] [Related]
2. Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin. Lundberg BB; Griffiths G; Hansen HJ Int J Pharm; 2000 Sep; 205(1-2):101-8. PubMed ID: 11000546 [TBL] [Abstract][Full Text] [Related]
3. Tumor targeting using anti-her2 immunoliposomes. Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487 [TBL] [Abstract][Full Text] [Related]
4. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells. Nam SM; Kim HS; Ahn WS; Park YS Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027 [TBL] [Abstract][Full Text] [Related]
5. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Sapra P; Moase EH; Ma J; Allen TM Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990 [TBL] [Abstract][Full Text] [Related]
6. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Lopes de Menezes DE; Pilarski LM; Allen TM Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662 [TBL] [Abstract][Full Text] [Related]
10. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130 [TBL] [Abstract][Full Text] [Related]
11. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Ishida T; Kirchmeier MJ; Moase EH; Zalipsky S; Allen TM Biochim Biophys Acta; 2001 Dec; 1515(2):144-58. PubMed ID: 11718670 [TBL] [Abstract][Full Text] [Related]
12. [Study on preparation and biodistribution of PEG-immunoliposomes with active carboxylic terminals]. Zhang YF; Xie SS; Hou XP; Gao X; Zhang S; Chen ZS Yao Xue Xue Bao; 2000 Nov; 35(11):854-9. PubMed ID: 11218866 [TBL] [Abstract][Full Text] [Related]
13. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394 [TBL] [Abstract][Full Text] [Related]
14. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Allen TM; Mumbengegwi DR; Charrois GJ Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261 [TBL] [Abstract][Full Text] [Related]
15. Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody. Lundberg BB; Griffiths G; Hansen HJ Drug Deliv; 2007 Mar; 14(3):171-5. PubMed ID: 17454037 [TBL] [Abstract][Full Text] [Related]
16. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Maruyama K; Takizawa T; Yuda T; Kennel SJ; Huang L; Iwatsuru M Biochim Biophys Acta; 1995 Mar; 1234(1):74-80. PubMed ID: 7880861 [TBL] [Abstract][Full Text] [Related]
17. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Allen TM; Brandeis E; Hansen CB; Kao GY; Zalipsky S Biochim Biophys Acta; 1995 Jul; 1237(2):99-108. PubMed ID: 7632714 [TBL] [Abstract][Full Text] [Related]
18. Immunotargeting of liposomes containing lipophilic antitumor prodrugs. Mori A; Kennel SJ; Huang L Pharm Res; 1993 Apr; 10(4):507-14. PubMed ID: 8483832 [TBL] [Abstract][Full Text] [Related]
19. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models. Apte A; Koren E; Koshkaryev A; Torchilin VP Cancer Biol Ther; 2014 Jan; 15(1):69-80. PubMed ID: 24145298 [TBL] [Abstract][Full Text] [Related]
20. Preparation and in vitro targeting of sterically stabilized liposomes modified with chimeric TNT-3 monoclonal antibody. Pan H; Niu GQ; Pan J; Lu WY Yao Xue Xue Bao; 2006 Jun; 41(6):506-12. PubMed ID: 16927823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]